search
Back to results

Right Ventricular Pacing in Pulmonary Arterial Hypertension

Primary Purpose

Pulmonary Artery Hypertension, Right Ventricular Dysfunction

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Temporary right ventricular pacing
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pulmonary Artery Hypertension

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients referred for a clinically indicated right heart catheterization to either diagnose pulmonary arterial hypertension prior to initiating therapies or monitor response to ongoing therapies in patients with diagnosed pulmonary arterial hypertension.
  • Patients with pulmonary arterial hypertension with or without significant right ventricular dysfunction as assessed by baseline echocardiography and standard of care right heart catheterization
  • Functional class 2 or 3 symptoms
  • Are able to undergo cardiac MRI, endocardial mapping, and pressure volume measurements
  • English speaking
  • All patients will be required to have evidence of right ventricular hypertrophy or conduction delay (QRS > 130ms) on surface ECG

Exclusion Criteria:

  • Preexisting left bundle branch block, current atrial fibrillation, or pacemaker/ defibrillators
  • Functional class 4 symptoms
  • Patients treated with parenteral or subcutaneous therapies for pulmonary hypertension
  • Contraindication to right heart catheterization including significant thrombocytopenia (platelets < 50,000), coagulopathy (INR > 1.8), or pregnancy as determined by routine screening laboratory work
  • Mean pulmonary artery pressure less than 25 mmHg as determined by the right heart catheterization on the day of the study procedure
  • Pulmonary capillary wedge pressure greater than or equal to 15 mmHg as determined by the right heart catheterization on the day of the study procedure
  • Severe tricuspid regurgitation as determined by baseline transthoracic echocardiogram.
  • Left ventricular dysfunction (EF < 50%) as determined by baseline transthoracic echocardiogram.
  • Inability to complete cardiac MRI or transthoracic echocardiography
  • Patients with confounding systemic disease specifically portopulmonary hypertension and scleroderma associated pulmonary hypertension
  • Patients otherwise deemed not appropriate for the study as determined by the study investigators

Sites / Locations

  • University of California San FranciscoRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Single Arm

Arm Description

All patients will undergo hemodynamic measurements at baseline, with the intervention, and post-intervention thus serving as their own control.

Outcomes

Primary Outcome Measures

Change in contractility (Ees)
This is an invasive measure of the contractile strength of the right ventricle that is measured using pressure volume measurements from within the ventricle itself.

Secondary Outcome Measures

Change in stroke volume
This is an invasive measure of the amount of blood ejected by the heart with each heart beat.
Pressure-volume loop area
The pressure-volume loop area will be calculated to assess right ventricular myocardial oxygen consumption
Coronary sinus oxygen saturation
Global myocardial oxygen consumption will also be assessed via measurement of the coronary sinus oxygen saturation.

Full Information

First Posted
December 9, 2019
Last Updated
April 28, 2021
Sponsor
University of California, San Francisco
search

1. Study Identification

Unique Protocol Identification Number
NCT04194632
Brief Title
Right Ventricular Pacing in Pulmonary Arterial Hypertension
Official Title
Right Ventricular Pacing to Treat Right Ventricular Failure: A Single Arm Hemodynamic Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
December 5, 2021 (Anticipated)
Study Completion Date
December 5, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In pulmonary arterial hypertension (PAH), progressive pulmonary vascular remodeling leads to supraphysiologic right ventricular (RV) afterload. Pharmacologic trials have shown that aggressive upfront treatment reversing pulmonary vascular remodeling successfully increases RV function and improves survival. To date, however, there are no proven treatments that target RV contractile function. Echocardiographic studies of RV dysfunction in the setting of pressure overload have demonstrated intra and interventricular dyssynchrony even in the absence of overt right bundle branch block (RBBB). Electrophysiologic studies of patients with chronic thromboembolic disease (CTEPH) at the time of pulmonary endarterectomy have shown prolongation of action potential and slowed conduction in the right ventricle which has correlated with echocardiographic measures of dyssynchrony. Cardiac MRI measures of RV strain in patients with PAH demonstrated simultaneous initiation of RV and left ventricular (LV) contraction, but delayed peak RV strain suggesting that interventricular dyssynchrony is a mechanical rather than electrical phenomenon. Prior studies of RV dysfunction in an animal model, computer model, congenital heart disease, and CTEPH have suggested acute hemodynamic benefits of RV pacing. However, RV pacing has not been studied in patients with PAH. Furthermore, it remains unclear if pacing particular regions of the RV can achieve a hemodynamic benefit and what cost this hemodynamic improvement may incur with regards to myocardial energetics and wall stress. Therefore, the investigators propose to examine RV electrical activation in PAH, map the area of latest activation, and then evaluate the hemodynamic and energetic effects of RV pacing in these patients.
Detailed Description
Research procedures in chronological order: Baseline clinical variables will be prospectively determined and then obtained retrospectively from the clinical assessment of individual pulmonary hypertension team physicians via chart review. The most recent transthoracic echocardiogram will also be evaluated and routine clinical variables including tricuspid annular plane systolic excursion (TAPSE), RV fractional area change (FAC), RV outflow tract (OT) and LVOT velocity time integral (VTI), and ejection fraction (EF) will be extracted. All patients will have cardiac MRI performed prior to the procedure to allow precise measurement of right ventricular volumes as well as LV volumes, RVEF, and LVEF. Gadolinium enhancement using gadolinium contrast will be measured. Standard of care right heart catheterization (RHC) will be performed on the day of the research procedure. Radial arterial pressure will be used for periprocedural monitoring as well as for sampling of arterial oxygen content and arterial oxygen lactate. Myocardial energetics will be assessed via sampling of coronary sinus venous blood with measurement of oxygen saturation and lactate. Following the standard of care RHC, endocardial mapping will be performed. After pressure-volume measurements are obtained (step 7), pacing will be performed from the right atrium (RA), His bundle, and RV at the site of the latest activation with repeat measurements of pressure-volume relationships. Once endocardial mapping is complete, a 7-French Millar conductance catheter will be placed into the RV and used to obtain pressure-volume data for the RV using the INCA PV signal processor. The Valsalva maneuver will be used to generate a series of PV-loops reflecting preload reduction subsequently allowing for the calculation of a load independent measure of contractility, the end systolic pressure volume relationship (Ees). RV afterload will be measured as effective arterial elastance (Ea) and V-A coupling will be assessed by the ratio of Ees/Ea. Myocardial energetics will be assessed via PV area (PVA) and calculation of the transmyocardial arteriovenous oxygen extraction.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Artery Hypertension, Right Ventricular Dysfunction

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
As described previously, patients will undergo measurements at baseline, with pacing, and post pacing and will thus function as their own control.
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Single Arm
Arm Type
Experimental
Arm Description
All patients will undergo hemodynamic measurements at baseline, with the intervention, and post-intervention thus serving as their own control.
Intervention Type
Procedure
Intervention Name(s)
Temporary right ventricular pacing
Intervention Description
As described previously. Patients will undergo temporary pacing at the site of latest endocardial activation with measurement of hemodynamic effects.
Primary Outcome Measure Information:
Title
Change in contractility (Ees)
Description
This is an invasive measure of the contractile strength of the right ventricle that is measured using pressure volume measurements from within the ventricle itself.
Time Frame
During procedure. The measurement will be taken pre-RV pacing, with RV pacing, and 5 minutes after RV pacing. All catheters will then be removed and the study will be completed.
Secondary Outcome Measure Information:
Title
Change in stroke volume
Description
This is an invasive measure of the amount of blood ejected by the heart with each heart beat.
Time Frame
During procedure. The measurement will be taken pre-RV pacing, with RV pacing, and 5 minutes after RV pacing. All catheters will then be removed and the study will be completed.
Title
Pressure-volume loop area
Description
The pressure-volume loop area will be calculated to assess right ventricular myocardial oxygen consumption
Time Frame
During procedure. The measurement will be taken pre-RV pacing, with RV pacing, and 5 minutes after RV pacing. All catheters will then be removed and the study will be completed.
Title
Coronary sinus oxygen saturation
Description
Global myocardial oxygen consumption will also be assessed via measurement of the coronary sinus oxygen saturation.
Time Frame
During procedure. The measurement will be taken pre-RV pacing, with RV pacing, and 5 minutes after RV pacing. All catheters will then be removed and the study will be completed.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients referred for a clinically indicated right heart catheterization to either diagnose pulmonary arterial hypertension prior to initiating therapies or monitor response to ongoing therapies in patients with diagnosed pulmonary arterial hypertension. Patients with pulmonary arterial hypertension with or without significant right ventricular dysfunction as assessed by baseline echocardiography and standard of care right heart catheterization Functional class 2 or 3 symptoms Are able to undergo cardiac MRI, endocardial mapping, and pressure volume measurements English speaking All patients will be required to have evidence of right ventricular hypertrophy or conduction delay (QRS > 130ms) on surface ECG Exclusion Criteria: Preexisting left bundle branch block, current atrial fibrillation, or pacemaker/ defibrillators Functional class 4 symptoms Patients treated with parenteral or subcutaneous therapies for pulmonary hypertension Contraindication to right heart catheterization including significant thrombocytopenia (platelets < 50,000), coagulopathy (INR > 1.8), or pregnancy as determined by routine screening laboratory work Mean pulmonary artery pressure less than 25 mmHg as determined by the right heart catheterization on the day of the study procedure Pulmonary capillary wedge pressure greater than or equal to 15 mmHg as determined by the right heart catheterization on the day of the study procedure Severe tricuspid regurgitation as determined by baseline transthoracic echocardiogram. Left ventricular dysfunction (EF < 50%) as determined by baseline transthoracic echocardiogram. Inability to complete cardiac MRI or transthoracic echocardiography Patients with confounding systemic disease specifically portopulmonary hypertension and scleroderma associated pulmonary hypertension Patients otherwise deemed not appropriate for the study as determined by the study investigators
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Benjamin Kelemen, MD
Phone
415-476-2143
Email
Benjamin.Kelemen@ucsf.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Liviu Klein, MD MS
Phone
415-476-2143
Email
Liviu.Klein@ucsf.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Liviu Klein, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Benjamin W Kelemen, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benjamin Kelemen, MD
Phone
415-476-2143
Email
benjamin.kelemen@ucsf.edu

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
18558476
Citation
Kalogeropoulos AP, Georgiopoulou VV, Howell S, Pernetz MA, Fisher MR, Lerakis S, Martin RP. Evaluation of right intraventricular dyssynchrony by two-dimensional strain echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr. 2008 Sep;21(9):1028-34. doi: 10.1016/j.echo.2008.05.005. Epub 2008 Jun 16.
Results Reference
background
PubMed Identifier
19843924
Citation
Hardziyenka M, Campian ME, Bouma BJ, Linnenbank AC, de Bruin-Bon HA, Kloek JJ, van der Wal AC, Baan J Jr, de Beaumont EM, Reesink HJ, de Bakker JM, Bresser P, Tan HL. Right-to-left ventricular diastolic delay in chronic thromboembolic pulmonary hypertension is associated with activation delay and action potential prolongation in right ventricle. Circ Arrhythm Electrophysiol. 2009 Oct;2(5):555-61. doi: 10.1161/CIRCEP.109.856021. Epub 2009 Aug 4.
Results Reference
background
PubMed Identifier
18279740
Citation
Marcus JT, Gan CT, Zwanenburg JJ, Boonstra A, Allaart CP, Gotte MJ, Vonk-Noordegraaf A. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. J Am Coll Cardiol. 2008 Feb 19;51(7):750-7. doi: 10.1016/j.jacc.2007.10.041.
Results Reference
background
PubMed Identifier
21784747
Citation
Hardziyenka M, Surie S, de Groot JR, de Bruin-Bon HA, Knops RE, Remmelink M, Yong ZY, Baan J Jr, Bouma BJ, Bresser P, Tan HL. Right ventricular pacing improves haemodynamics in right ventricular failure from pressure overload: an open observational proof-of-principle study in patients with chronic thromboembolic pulmonary hypertension. Europace. 2011 Dec;13(12):1753-9. doi: 10.1093/europace/eur189. Epub 2011 Jul 21.
Results Reference
background
PubMed Identifier
19734361
Citation
Handoko ML, Lamberts RR, Redout EM, de Man FS, Boer C, Simonides WS, Paulus WJ, Westerhof N, Allaart CP, Vonk-Noordegraaf A. Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart. Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1752-9. doi: 10.1152/ajpheart.00555.2009. Epub 2009 Sep 4.
Results Reference
background
PubMed Identifier
19837949
Citation
Lumens J, Arts T, Broers B, Boomars KA, van Paassen P, Prinzen FW, Delhaas T. Right ventricular free wall pacing improves cardiac pump function in severe pulmonary arterial hypertension: a computer simulation analysis. Am J Physiol Heart Circ Physiol. 2009 Dec;297(6):H2196-205. doi: 10.1152/ajpheart.00870.2009. Epub 2009 Oct 16.
Results Reference
background
PubMed Identifier
28877886
Citation
Janousek J, Kovanda J, Lozek M, Tomek V, Vojtovic P, Gebauer R, Kubus P, Krejcir M, Lumens J, Delhaas T, Prinzen F. Pulmonary Right Ventricular Resynchronization in Congenital Heart Disease: Acute Improvement in Right Ventricular Mechanics and Contraction Efficiency. Circ Cardiovasc Imaging. 2017 Sep;10(9):e006424. doi: 10.1161/CIRCIMAGING.117.006424.
Results Reference
background

Learn more about this trial

Right Ventricular Pacing in Pulmonary Arterial Hypertension

We'll reach out to this number within 24 hrs